Your Followed Topics

Top 2 piper sandler News Today

#1
Chart analysts caution not to chase this comeback rally
#1 out of 2
business1d ago

Chart analysts caution not to chase this comeback rally

  • The S&P 500 climbed modestly after Trump said talks with Iran were productive, but the gains may be short-lived.
  • Analysts warned the rally could be a relief move without changing the longer-term downtrend.
  • Analysts projected the S&P 500 could rise to around 6,900 in the near term but see a potential drop to about 6,175 later.
  • The Russell 2000 entered correction territory, signaling broader weakness in small caps last week.
  • Major indices briefly joined the decline before Monday’s rebound, signaling fragility in late-week trading.
  • Analysts emphasized watching key resistance at the 200-day and 20-day moving averages.
  • Market fear gauge has not spiked above 35, suggesting a moderation in selling pressure for now.
  • One analyst framed Monday’s activity as relief rather than a new sustained uptrend.
  • The overall tone suggests cautious positioning amid ongoing geopolitical tensions and volatility.
  • Analysts expect potential downside in the S&P 500 over the next six months despite a near-term bounce.
  • The report underscores a cautious stance among technical analysts regarding a sustained rally.
Vote 0
0
#2
Generate Biomedicines gains buy initiations from Guggenheim, Piper Sandler
#2 out of 2
business10h ago

Generate Biomedicines gains buy initiations from Guggenheim, Piper Sandler

  • Guggenheim initiates coverage on Generate Biomedicines with a buy rating, signaling institutional interest.
  • Piper Sandler also starts coverage with a buy rating, expanding the stock's analyst support.
  • Analysts cite Generate Biomedicines’ pipeline potential as a catalyst for upside.
  • The news could attract further institutional attention to the company.
  • Generate Biomedicines is positioned as a potential beneficiary of pharmaceutical industry innovation.
  • The coverage comes amid broader investor focus on early-stage biotech catalysts.
  • No clinical data was released in the report, but ratings reflect sentiment.
  • The article emphasizes market curiosity about Generate Biomedicines’ platform technology.
  • The report may influence short-term trading as investors reassess risk and reward.
  • Generate Biomedicines’ shares could react to further broker updates and market visibility.
Vote 0
0

Explore Your Interests

Unlimited Access
Personalized Feed
Full Experience
or
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Explore Your Interests

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access
Personalized Feed
Full Experience
or
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Advertisement

Advertisement